

## **Hybrigenics unveils a lead chemical structure for its discovery of new anticancer drugs**

### **Article in Molecular Cancer Therapeutics shows the anticancer potential of an inhibitor of ubiquitin-specific protease n<sup>7</sup>**

**Paris, 24 August 2009** – Hybrigenics (ALHYG), a bio-pharmaceutical company listed on Alternext (NYSE-Euronext) in Paris, with a focus on research and development of new cancer treatments and specialized in protein interactions, today announces the publication of a scientific article in Molecular Cancer Therapeutics showing the anticancer potential of HBX 41,108, its lead small molecule inhibitor of ubiquitin-specific protease n<sup>7</sup> (USP7).

Many cancer types from different organs are dependent on the crucial tumor-suppressor protein called p53, which is regulated by USP7. The article published in Molecular Cancer Therapeutics describes how Hybrigenics has demonstrated that small molecules can inhibit USP7 activity, resulting in the activation of functional p53 and in the growth inhibition of p53-dependent cancer cell lines. HBX 41,108 is the lead compound of such USP7 inhibitors, with a demonstrated potential to become an innovative anticancer drug candidate after further chemical optimization.

Molecular Cancer Therapeutics is a highly-ranked international scientific journal accepting articles for publication after an academic peer-reviewed process with stringent acceptance criteria for novelty, relevance to the field and strength of experimental evidence. "*This publication highlights the recognition by the scientific community of our pioneer research position in the field of USP inhibition*", said Frédéric Colland, Head of Biological Research at Hybrigenics.

Reference: Colland *et al.*, Mol Cancer Ther (2009) 8, 2286-95  
Link: <http://mct.aacrjournals.org/content/8/8/2286.abstract>

#### **About Hybrigenics**

Hybrigenics ([www.hybrigenics.com](http://www.hybrigenics.com)) is a bio-pharmaceutical company listed (ALHYG) on Alternext (NYSE-Euronext) in Paris, focusing its internal R&D programs on innovative targets and therapies for the treatment of cancer. Hybrigenics' development program is based on inecalcitol, a vitamin D analogue, for the treatment of hormone-refractory prostate cancer in combination with Sanofi-Aventis' Taxotere<sup>®</sup>, which is the current gold-standard chemotherapeutic treatment for this indication. Hybrigenics' research program explores the role of enzymes known as ubiquitin-specific proteases (USP) in the degradation of onco-proteins, and the effectiveness of proprietary USP inhibitors in treating various types of cancer.

Hybrigenics is also the market leader in Yeast-Two Hybrid (Y2H) and related services to identify, validate and inhibit protein interactions for researchers in all areas of life sciences, using its ISO 9001-certified high-throughput Y2H screening platform, its sophisticated bioinformatics tools and extensive database, along with its chemical library and chemical screening platform.

\*\*\*

**HYBRIGENICS is listed on the Alternext by NYSE Euronext**

**ISIN: FR0004153930 / Ticker: ALHYG**